Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment.

Next Previous
Trial Profile

A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibuprofen/famotidine (Primary) ; Ibuprofen
  • Indications Back pain; Musculoskeletal pain; NSAID-induced ulcer; Osteoarthritis; Rheumatoid arthritis
  • Focus Adverse reactions; Registrational
  • Acronyms REDUCE-2
  • Sponsors Amgen

Most Recent Events

  • 20 Dec 2011 Results from a pooled analysis (REDUCE-1 and REDUCE-2) published in the American Journal of Gastroenterology.
  • 25 Apr 2011 Based on the results of this and the REDUCE-1 trial, the US FDA approved ibuprofen/famotidine for the reduction of the risk of development of upper gastrointestinal ulcers in patients with rheumatoid arthritis or osteoarthritis.
  • 03 Nov 2010 Results will be presented at the 74th Annual Scientific Meeting of the American College of Rheumatology and the 45th Annual Meeting of the Association of Rheumatology and Health Professionals, according to an Horizon Pharma media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top